首页> 外文期刊>Biosciences Biotechnology Research Asia >Phenotypic detection of High-Level Aminoglycoside Resistance (HLAR) in Enterococcus species in a tertiary care centre
【24h】

Phenotypic detection of High-Level Aminoglycoside Resistance (HLAR) in Enterococcus species in a tertiary care centre

机译:三级医疗中心肠球菌中高水平氨基糖苷抗性(HLAR)的表型检测

获取原文
获取原文并翻译 | 示例
           

摘要

Enterococcus is one of the important causes of hospital acquired infections. Drug resistance particularly for High Level Aminoglycosides Resistance is one of the important patterns of resistance exhibited by Enterococcus. This study was conducted to determine the high-level aminoglycoside resistance for gentamicin and streptomycin in Enterococcal species isolated from a tertiary care centre. Number of isolates collected were 76 of which 42 (55.2%) from urine 26(34.21%) from exudates, 4(5.26%) from blood and rest from other body fluids. Most of the isolates were Enterococcus faecalis (72%) followed by Enterococcus faecium (28%). All the isolates were subjected to Kirby-Bauer disk diffusion test using high-content gentamicin (120 mu g/disk) and streptomycin (300 mu g/disk), single concentration agar dilution test with streptomycin 2000 mu g/ml, 500 mu g/ml and 2000 mu g/ml of gentamicin. There were 27 (35.5%) were showed High Level Aminoglycosides Resistance (HLAR), of which 18(23.68%) were High Level Gentamycin Resistance (HLGR), 9(11.84%) were High Level Streptomycin Resistance (HLSR) and 9 (11.84%) isolates showed resistant to both. E.faecalis was the species most frequently exhibited High Level Resistance (HLR) for the drugs tested. Prevalence of HLAR in Enterococci is high and could be a serious problem in a hospital setup, screening for high-level aminoglycoside resistance must be included in routine antibiotic susceptibility reporting for Enterococcal isolates, especially from blood as high-level resistant strains does not show synergism with cell wall acting antibiotics like penicillin group and vancomycin which are the drug of choice.
机译:肠球菌是医院获得性感染的重要原因之一。耐药性,尤其是对高水平氨基糖苷类药物的耐药性是肠球菌表现出的重要耐药性模式之一。进行这项研究以确定从三级护理中心分离的肠球菌物种中庆大霉素和链霉素的高水平氨基糖苷抗性。收集到的分离株为76种,其中42种(55.2%)来自尿液26种(34.21%)来自渗出液,4种(5.26%)来自血液,其余来自其他体液。大多数分离株是粪肠球菌(72%),其次是粪肠球菌(28%)。所有分离物均采用高含量庆大霉素(120微克/片)和链霉素(300微克/片)进行Kirby-Bauer圆盘扩散试验,链霉素2000微克/毫升,500微克的单浓度琼脂稀释试验/ ml和2000μg/ ml庆大霉素。高氨基糖苷耐药性(HLAR)占27(35.5%),其中高庆他霉素耐药(HLGR)18(23.68%),高链霉素耐药(HLSR)9(11.84%)和9(11.84) %)分离株显示出对两者的抗性。粪肠球菌是所测试药物中最常见的高水平抗药性(HLR)物种。肠球菌中HLAR的患病率很高,在医院中可能是一个严重的问题,对肠球菌分离株的常规抗生素敏感性报告中必须包括对高水平氨基糖苷耐药性的筛查,尤其是对血液的分离,因为高水平耐药株没有协同作用具有细胞壁作用的抗生素,如青霉素类和万古霉素是首选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号